CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $908 | -19.1% | 20 | 0.0% | 0.00% | – |
| Q2 2023 | $1,123 | -84.0% | 20 | -87.1% | 0.00% | -100.0% |
| Q1 2023 | $7,011 | +11.3% | 155 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $6,301 | -99.9% | 155 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $10,129,000 | +7.5% | 155 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $9,419,000 | -1.1% | 155 | 0.0% | 0.00% | +33.3% |
| Q1 2022 | $9,525,000 | -96.0% | 155 | -95.0% | 0.00% | -96.2% |
| Q4 2021 | $236,434,000 | -32.3% | 3,120 | 0.0% | 0.08% | -38.9% |
| Q3 2021 | $349,222,000 | -30.9% | 3,120 | 0.0% | 0.13% | -34.2% |
| Q2 2021 | $505,097,000 | +32.9% | 3,120 | 0.0% | 0.20% | +26.8% |
| Q1 2021 | $380,172,000 | +123734.5% | 3,120 | -58.4% | 0.16% | -15.6% |
| Q3 2019 | $307,000 | – | 7,500 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |